Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
The Present Efficacy of Multiple Sclerosis Therapeutics
Neurol 73:984-990, Klawiter,E.,et al, 2009
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 69:1552-1553, Sorenson,P.S. &Bertolotto,A., 2007
Neutralizing Anti-IFN-B Antibodies
Neurol 65:6-8, Giovannoni,G.&Goodman,A., 2005
Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Multiple Sclerosis
NEJM 343:938-952, Noseworthy,J.H. et al, 2000
Multiple Sclerosis,Therapeutic Update
Arch Neurol 56:277-280, Tselis,A.C.&Lisak,R.P., 1999
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Treatment Recommendations for Interferon-B in Multiple Sclerosis
JNNP 67:561-566, Polman,C.H.,et al, 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Current Immunotherapy in Multiple Sclerosis
Immunology and Cell Biology 76:55-64, Bashir,K.&Whitaker,J.N., 1998
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
The Interferons:Biological Effects, Mechanisms of Action, and Use in Multiple Sclerosis
Ann Neurol 37:7-15, Weinstock-Guttman,B.,et al, 1995
Numb Chin Syndrome
UptoDate.com Sept, Robertson, C.E., 2018
Nocardiosis of the Central Nervous System
Medicine 93:19-32, Anagnostou, T.,et al, 2014
Intracranial Neoplasms and Paraneoplastic Disorders, Primary Central Nervous System Lymphoma
Adams & Victors Principles of Neurology, Chp 31, pg 658, Ropper, A.H.,et al, 2014
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Clinical and Biomarker Changes in Dominantly Inherited Alzheimers Disease
NEJM 367:795-804,864, Bateman, R.J.,et al, 2012
Central Nervous System Lymphoma: Characteristic Findings on Traditional and Advanced Imaging
AJNR 32:984-992, Haldorsen, I.S.,et al, 2011
Small Fiber Neuropathy: A Burning Problem
Cleve Clin J Med 76:297-305, Tavee, J. & Zhou, L., 2009
CT and MRI Findings of Intracranial Lymphoma
AJR 184:1679-1685, Slone,H.W.,et al, 2005
Clinical Features and Diagnosis of Primary Central Nervous System Lymphoma
Hematol Oncol Clin North Am 19:689-703, Fitzsimmons,A.,et al, 2005
Primary Lymphoma of the Central Nervous System: Typical and Atypical CT and MR Imaging Appearances
AJR 176:1319-1326, Erdag,N.,et al, 2001
Role of Brain Biopsy in the Management of Focal Brain Lesions in HIV-Infected Patients
Neurol 54:993-997, Antinori,A.,et al, 2000
Epstein-Barr Virus Infection
NEJM 343:481-492, Cohen,J.I., 2000
Brain Biopsy in Patients with Acquired Immunodeficiency Syndrome, Diagnostic Value, Clinical Performance, and Survival Time
Arch Int Med 159:2590-2596, Hornef,M.W.,et al, 1999
Evaluation and Management of Intracranial Mass Lesions in AIDS
Rpt of Quality Stnds Subcomm of the AAN, Neurol 50:21-261998., , 1998
Acute Leukoencephalopathies:Differential Diagnosis and Investigation
The Neurologist 4:148-166, Weinshenker,B.G.,et al, 1998
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
The Variable MR Appearance of Primary Lymphoma of the Central Nervous System:Comparison with Histopathologic Features
AJNR 18:563-572, Johnson,B.A.,et al, 1997
AIDS and Cerbrovascular Disease
Stroke 27:538-543, Pinto,A.N., 1996
Neuroimaging Findings in Patients with AIDS
Clin Inf Dis 22:906-919, Walot,I.,et al, 1996
Neoplasms, In AIDS and Neurology
Churchill Livingstone, NY, Ch 12, 18395., Harrison,M.J.G.&McArthur,J.C., 1995
Current Management of Primary Central Nervous Lymphoma
Oncology 9:63-78, DeAngelis,L.M., 1995
Neurologic Manifestations of HIV Infection
Ann Int Med 121:769-785, Simpson,D.M.&Tagliati,M., 1994
AIDS-Associated Malignant Lymphoma
In Textbook of AIDS Medicine, Williams & Wilkins, Balt p. 431., Knowles,D.M.&Dalla-Favera,R., 1994
Lymphoma:Clin Char & Diagn
In AIDS Knowledge Base, 2nd Ed, Little, Brown & Co, Boston, 7:5-1, Kaplan,L.D., 1994
Primary Central Nervous System Lymphoma
Ann Int Med 119:1093-1104, Fine,H.A.&Mayer,R.J., 1993
Brain Imaging in Human Immunodeficiency Virus Infection
Semin Neurol 12:57-69, Ketonen,L.&Tuite,M.J., 1992
Primary Cerebral Lymphoma in Patients with AIDs:MR Findings in 17 Cases
AJR 159:841-847, Cordoliani,Y.,et al, 1992
Primary Central Nervous System Lymphomas-An Update
J Cancer Res Clin Oncol 119:7-27, Jellinger,K.A.&Paulus,W., 1992
CT Appearance of Primary CNS Lymphoma in Patients with Acquired Immunodeficiency Syndrome
J Comput Assist Tomogr 15:39-44, Goldstein,J.D.,et al, 1991